Genomics Market: Next-Generation Sequencing Expansion, Clinical Research & Market Forecast

Rapid genomics market growth is driven by declining sequencing costs, expanding clinical adoption, and strong investment in precision medicine. Advances in next-generation sequencing, bioinformatics, and AI improve data accuracy and scalability. According to IMARC Group's latest research publication, global genomics market size reached USD 38.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 113.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.77% during 2025-2033.

How AI is Reshaping the Future of Genomics Market

• Accelerating Variant Classification and Interpretation: AI models trained on large genomic datasets classify variants of uncertain significance with remarkable accuracy, helping clinicians determine pathogenicity for better patient management decisions.
• Optimizing CRISPR Gene Editing Design: Machine learning algorithms predict off-target effects and optimize guide RNA design in CRISPR-Cas9 systems, ensuring safer and more efficient gene-editing outcomes for therapeutic applications targeting genetic disorders and inherited conditions.
• Automating Functional Genomics Research: Large language models like GPT-4 achieve 73% accuracy in identifying common gene functions from curated datasets, potentially saving researchers countless hours of intensive labor in gene set enrichment analysis.

Explore Verified Market Data and Forecasts in a Sample Report

Genomics Industry Overview:

The genomics landscape is experiencing transformative growth driven by technological breakthroughs and substantial investment. The UK's Genomics England Diverse Data initiative received £22.0 million funding to reduce health inequities across minority communities. Australia committed ongoing funding to establish Genomics Australia within its federal government structure. The U.S. National Human Genome Research Institute launched technology development programs supporting novel laboratory tools for clinical applications.

Genomics Market Trends & Drivers:

The explosive adoption of next-generation sequencing technologies across clinical diagnostics is driving unprecedented market expansion. NGS platforms enable comprehensive cancer screening, rare disease identification, and infectious disease monitoring with remarkable accuracy and speed. Illumina launched its Complete Long Read technology compatible with NovaSeq platforms, providing high-performance whole-genome sequencing capabilities.

Strategic partnerships and acquisitions are reshaping competitive dynamics as companies consolidate capabilities to deliver integrated solutions. In April 2025, GeneDx acquired Fabric Genomics for approximately $50 million, combining genomic diagnostics expertise with AI-powered interpretation platforms to enable decentralized testing with centralized intelligence. Singular Genomics Systems completed its acquisition by Deerfield Management Company, strengthening next-generation sequencing and spatial multiomics technologies..

Personalized medicine adoption and expanded clinical applications are creating sustained demand across pharmaceutical, biotechnology, and healthcare sectors. Genomic testing now guides treatment decisions for conditions including Alzheimer's, diabetes, and various cancers, with oncology applications leading adoption rates. Non-invasive prenatal testing and liquid biopsy technologies are expanding diagnostic capabilities beyond traditional laboratory settings.

Leading Companies Operating in the Global Genomics Industry:

• 23andMe, Inc
• Agilent Technologies, Inc.
• Bayer AG
• BGI Group
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Illumina, Inc.
• Oxford Nanopore Technologies
• PerkinElmer, Inc.
• Myriad Genetics, Inc.
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.

Genomics Market Report Segmentation:

By Component:

• Products
• Instruments and Software
• Consumables and Reagents
• Services
• Core Genomics Services
• NGS-Based Services
• Biomarker Translation Services
• Computational Services
• Others

Consumables and reagents represent the largest segment, as these essential materials are required for DNA sequencing, gene editing, and sample preparation across all genomic procedures.

By Application:

• Functional Genomics
• Epigenomics
• Biomarkers Discovery
• Pathway Analysis
• Others

Functional genomics holds the largest share owing to its focus on understanding gene functions and interactions using high-throughput technologies including RNA sequencing and CRISPR-Cas9.

By Technology:

• Sequencing
• Microarray
• Polymerase Chain Reaction
• Nucleic Acid Extraction and Purification
• Others

Sequencing represents the leading segment due to its critical role in deciphering genetic information, with next-generation sequencing providing unprecedented speed, accuracy, and cost-efficiency.

By End-User:

• Research Centers
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Others

Pharmaceutical and biotechnology companies exhibit clear dominance, utilizing genomic data for drug target identification, disease understanding, and personalized treatment development.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits clear dominance owing to advanced healthcare infrastructure, significant research investment, and presence of leading pharmaceutical and biotechnology companies.

Recent News and Developments in Genomics Market:

• June 2025: Enhanced Genomics appointed Dietrich Stephan, Ph.D. as Chair of the Board of Directors to lead strategic expansion of its internal target identification pipeline for common diseases, with initial focus on autoimmune indications and establishing partnerships for drug discovery.
• May 2025: SeqOne secured €20 million in oversubscribed growth funding led by Supernova Invest, with continued support from Elaia, Omnes, and Merieux Equity Partners, to expand global operations and strengthen leadership in transforming patient care through genomic insights.
• April 2025: Valted Seq, Inc. launched Single Cell AI Discovery Engine (SCADE), an AI-powered genomics device incorporating advanced machine learning algorithms to revolutionize interpretation of genetic data, accelerating biomarker discovery and personalized medicine development.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.